SIGACHI37.60

Sigachi Industries Limited

· Pharma & Health
₹ CrorePeersLINCOLNTHEMISMEDBAJAJHCAREAMRUTANJANJAGSNPHARMWANBURYNGLFINEMcap ₹1,437 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Returns
Return on Common Equity12.9711.35-15.46-15.46
Return on Assets8.258.33-9.84-9.84
Return on Capital Employed13.0112.746.346.34
Return on Invested Capital9.548.715.314.49
Margins
EBITDA Margin19.2120.4811.259.80
Operating Margin16.5117.257.577.57
Incremental Operating Margin20.56461.74
Pretax Margin17.4918.91-18.354.97
Net Income Margin14.3514.43-17.335.59
Net Income to Common Margin14.3314.25-17.115.38
FCF Margin-18.12-3.36-7.71-7.71
Additional
Effective Tax Rate17.9223.685.58-12.50
Dvd Payout Ratio5.374.66-4.61
Sustainable Growth Rate12.2710.82-16.17-15.46
Incremental Operating Margin %20.56461.74104.37
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.